PharmaEssentia Corporation, a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver novel hematology and oncology biologics, has announced reported that the first patients are now receiving treatment from ECLIPSE PV, a phase 3b clinical study evaluating an accelerated dosing regimen for cordeginterferon alfa. -2b-njft uses a prefilled syringe to treat polycythemia vera (PV) in adults.
In November 2021, the US Food and Drug Administration approved Besrem injection for adults with polycythemia vera, a blood disorder that causes overproduction of red blood cells. The extra cells thicken the blood, slowing blood flow and increasing the chance of blood clots.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5256
Published Date: Sep 25, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of polycythemia vera and increasing awareness about polycythemia vera treatment are some of the major factors anticipated to drive
The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are Pfizer Inc., Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Viatris Inc. and others.
The oral segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.